Multimodality treatment of locally advanced breast carcinoma

P. C. Hobar, R. C. Jones, J. Schouten, A. M. Leitch, F. Hendler

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Forty patients with 41 locally advanced breast lesions at stages IIIA and IIIB and the inflammatory stage were treated with combined-modality therapy from July 1980 to August 1985. Treatment included induction chemotherapy consisting of three cycles of fluorouracil, doxorubicin hydrochloride, and cyclophosphamide, followed by mastectomy in those patients whose lesions were operable (n=28), and resumption of chemotherapy. Nine patients received postoperative radiation therapy. The mean follow-up was 34 months. Greater than 50% reduction in tumor size was achieved in 72% of patients after three cycles of chemotherapy. Overall, local control was achieved in 85% of patients with 59% survival and 53% disease-free survival, while 10% of patients developed local recurrences. Excluding lymphedema of the upper extremity (n=2) and inflammatory carcinomas (n=4), local control was achieved in 96% of patients, with 75% survival and 68% disease-free survival, while 4% of patients developed local recurrences. The rate of disease-free survival was 71% in patients with partial response to chemotherapy, contrasted with 43% in patients who did not respond or only minimally responded to chemotherapy. Actuarial five-year survival, based on life-table analysis, was calculated to be 46% for the group overall, 58% for the group excluding lymphedema of the upper extremity and inflammatory carcinoma, and 56% for the 28 patients undergoing mastectomy.

Original languageEnglish (US)
Pages (from-to)951-955
Number of pages5
JournalArchives of Surgery
Volume123
Issue number8
StatePublished - 1988

Fingerprint

Breast Neoplasms
Therapeutics
Disease-Free Survival
Drug Therapy
Lymphedema
Mastectomy
Upper Extremity
Survival
Carcinoma
Recurrence
Combined Modality Therapy
Induction Chemotherapy
Life Tables
Fluorouracil
Doxorubicin
Cyclophosphamide
Breast
Radiotherapy
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Hobar, P. C., Jones, R. C., Schouten, J., Leitch, A. M., & Hendler, F. (1988). Multimodality treatment of locally advanced breast carcinoma. Archives of Surgery, 123(8), 951-955.

Multimodality treatment of locally advanced breast carcinoma. / Hobar, P. C.; Jones, R. C.; Schouten, J.; Leitch, A. M.; Hendler, F.

In: Archives of Surgery, Vol. 123, No. 8, 1988, p. 951-955.

Research output: Contribution to journalArticle

Hobar, PC, Jones, RC, Schouten, J, Leitch, AM & Hendler, F 1988, 'Multimodality treatment of locally advanced breast carcinoma', Archives of Surgery, vol. 123, no. 8, pp. 951-955.
Hobar PC, Jones RC, Schouten J, Leitch AM, Hendler F. Multimodality treatment of locally advanced breast carcinoma. Archives of Surgery. 1988;123(8):951-955.
Hobar, P. C. ; Jones, R. C. ; Schouten, J. ; Leitch, A. M. ; Hendler, F. / Multimodality treatment of locally advanced breast carcinoma. In: Archives of Surgery. 1988 ; Vol. 123, No. 8. pp. 951-955.
@article{a800cb688afb4c38ac816641bcec6951,
title = "Multimodality treatment of locally advanced breast carcinoma",
abstract = "Forty patients with 41 locally advanced breast lesions at stages IIIA and IIIB and the inflammatory stage were treated with combined-modality therapy from July 1980 to August 1985. Treatment included induction chemotherapy consisting of three cycles of fluorouracil, doxorubicin hydrochloride, and cyclophosphamide, followed by mastectomy in those patients whose lesions were operable (n=28), and resumption of chemotherapy. Nine patients received postoperative radiation therapy. The mean follow-up was 34 months. Greater than 50{\%} reduction in tumor size was achieved in 72{\%} of patients after three cycles of chemotherapy. Overall, local control was achieved in 85{\%} of patients with 59{\%} survival and 53{\%} disease-free survival, while 10{\%} of patients developed local recurrences. Excluding lymphedema of the upper extremity (n=2) and inflammatory carcinomas (n=4), local control was achieved in 96{\%} of patients, with 75{\%} survival and 68{\%} disease-free survival, while 4{\%} of patients developed local recurrences. The rate of disease-free survival was 71{\%} in patients with partial response to chemotherapy, contrasted with 43{\%} in patients who did not respond or only minimally responded to chemotherapy. Actuarial five-year survival, based on life-table analysis, was calculated to be 46{\%} for the group overall, 58{\%} for the group excluding lymphedema of the upper extremity and inflammatory carcinoma, and 56{\%} for the 28 patients undergoing mastectomy.",
author = "Hobar, {P. C.} and Jones, {R. C.} and J. Schouten and Leitch, {A. M.} and F. Hendler",
year = "1988",
language = "English (US)",
volume = "123",
pages = "951--955",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Multimodality treatment of locally advanced breast carcinoma

AU - Hobar, P. C.

AU - Jones, R. C.

AU - Schouten, J.

AU - Leitch, A. M.

AU - Hendler, F.

PY - 1988

Y1 - 1988

N2 - Forty patients with 41 locally advanced breast lesions at stages IIIA and IIIB and the inflammatory stage were treated with combined-modality therapy from July 1980 to August 1985. Treatment included induction chemotherapy consisting of three cycles of fluorouracil, doxorubicin hydrochloride, and cyclophosphamide, followed by mastectomy in those patients whose lesions were operable (n=28), and resumption of chemotherapy. Nine patients received postoperative radiation therapy. The mean follow-up was 34 months. Greater than 50% reduction in tumor size was achieved in 72% of patients after three cycles of chemotherapy. Overall, local control was achieved in 85% of patients with 59% survival and 53% disease-free survival, while 10% of patients developed local recurrences. Excluding lymphedema of the upper extremity (n=2) and inflammatory carcinomas (n=4), local control was achieved in 96% of patients, with 75% survival and 68% disease-free survival, while 4% of patients developed local recurrences. The rate of disease-free survival was 71% in patients with partial response to chemotherapy, contrasted with 43% in patients who did not respond or only minimally responded to chemotherapy. Actuarial five-year survival, based on life-table analysis, was calculated to be 46% for the group overall, 58% for the group excluding lymphedema of the upper extremity and inflammatory carcinoma, and 56% for the 28 patients undergoing mastectomy.

AB - Forty patients with 41 locally advanced breast lesions at stages IIIA and IIIB and the inflammatory stage were treated with combined-modality therapy from July 1980 to August 1985. Treatment included induction chemotherapy consisting of three cycles of fluorouracil, doxorubicin hydrochloride, and cyclophosphamide, followed by mastectomy in those patients whose lesions were operable (n=28), and resumption of chemotherapy. Nine patients received postoperative radiation therapy. The mean follow-up was 34 months. Greater than 50% reduction in tumor size was achieved in 72% of patients after three cycles of chemotherapy. Overall, local control was achieved in 85% of patients with 59% survival and 53% disease-free survival, while 10% of patients developed local recurrences. Excluding lymphedema of the upper extremity (n=2) and inflammatory carcinomas (n=4), local control was achieved in 96% of patients, with 75% survival and 68% disease-free survival, while 4% of patients developed local recurrences. The rate of disease-free survival was 71% in patients with partial response to chemotherapy, contrasted with 43% in patients who did not respond or only minimally responded to chemotherapy. Actuarial five-year survival, based on life-table analysis, was calculated to be 46% for the group overall, 58% for the group excluding lymphedema of the upper extremity and inflammatory carcinoma, and 56% for the 28 patients undergoing mastectomy.

UR - http://www.scopus.com/inward/record.url?scp=0023785831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023785831&partnerID=8YFLogxK

M3 - Article

VL - 123

SP - 951

EP - 955

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 8

ER -